The levels of PRL did not relate to most clinical conditions considered, including cardiovascular diseases (myocardial infarct, congestive heart failure, vascular disease and stroke), epilepsy, cancer or mortality (Table 2), except for an inverse relationship with diabetes: the prevalences of diabetes were 8.6%, 12.7% and 24.1% in patients within phase-1 PRL groups of 5.0-34.9 ng/ml to 3.0-4.9 ng/ml and 0.3–2.9 ng/ml, respectively. This evidence concerns the gene PRL and stroke disorder.